Back to News
Market Impact: 0.2
Canaccord Genuity initiates coverage of First Tracks Biotherapeutics with a Buy rating
Source: Nasdaq
Analyst InsightsHealthcare & Biotech
Canaccord Genuity initiated coverage of First Tracks Biotherapeutics (NASDAQGS: TRAX) with a Buy recommendation on September 30, 2026. The stock closed at $35.98 on September 29 ahead of the rating action; no price target or additional valuation rationale was provided.
AllMind Terminal
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Request TrialMarket Sentiment
Overall Sentiment
mildly positive
Sentiment Score
0.25
More News
- Middleby stock hits 52-week low at 104.23 USD
- BTIG cuts Connect Biopharma stock price target on trial timeline
- Why is Lynas Rare Earths stock sliding today?
- Micron capacity buildout: These equipment suppliers stand to benefit
- Walgreens owner nears $9 billion deal to sell Boots chain- WSJ
- Eli Lilly says closely watched combo obesity regimen boosts weight loss in mid-stage trial
From AllMind Research
- Anthropic IPO Preview: Valuation, Timing, and What to Watch
- Shein After the IPO: Venue, Valuation, and What Must Be Proved
- What AI Research Tools Should a Small Hedge Fund Buy First?
- How to Build an Automated Research Process for a Fund
- Weekly Update: AI-Powered Report Editing, Investor Relations, and Enhanced Search